Impact of SomaSignal Tests on the Choice of Glucose-lowering Medications

Inclusion Criteria: Provider * Licensed provider actively practicing medicine at a UC Health clinic that routinely provides medical treatment for patients with type 2 diabetes Inclusion Criteria: Patient * Patients receiving care at a UC Health system * Age 40 years or older * Type 2 Diabetes * Eligible for (per drug label/guidelines) at least one of the following classes: SGLT2i, PCSK9i, GLP-1 RA * Able to provide consent Exclusion Criteria: * Use of SGLT2i , GLP1RA and PCSK9i within the 3 months prior to enrollment * Systemic Lupus Erythematous (SLE)\* * Pregnancy (as determined by self report) * Intolerance or contraindication for use of both GLP1RA and SGLT2i * History of, an active, or untreated malignancy, in remission from a clinically significant malignancy (other than basal or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years prior to, or are receiving or planning to receive therapy for cancer, at screening * Samples provided by patients with SLE may fail to produce results or may produce inaccurate results because autoantibodies in the patient plasma may interact with the DNA-based reagents used in the assay